Articles

Qiming Star | One-Time Treatment, Long-Term Benefit: BBM-H901's First National Prescription Filled, Hemophilia B Care Enters Gene Therapy Era

Qiming Star | One-Time Treatment, Long-Term Benefit: BBM-H901's First National Prescription Filled, Hemophilia B Care Enters Gene Therapy Era

This milestone breakthrough not only marks the first domestically developed innovative gene therapy becoming available to hemophilia B patients in China, but also signals that treatment for the disease in the country has officially entered an entirely new era of gene therapy.

10 Q&As: A Deep Dive into the Divides in Embodied Robotics — A Conversation with the Founders and Chief Scientists of Sudu Tech, Ant Group's Lingbo, Independent Variable Robotics, and Poke Robotics

10 Q&As: A Deep Dive into the Divides in Embodied Robotics — A Conversation with the Founders and Chief Scientists of Sudu Tech, Ant Group's Lingbo, Independent Variable Robotics, and Poke Robotics

Where does the data come from? How is the model built? Where does it get deployed?

Yeats.AI Completes Pre-A Round Led by Shenzhen Capital Group, Heli Capital, TCL Ventures and CASSTAR, with Former Apple NPU Executives Betting on Edge General-Purpose Computing Platform | Unity Ventures

Yeats.AI Completes Pre-A Round Led by Shenzhen Capital Group, Heli Capital, TCL Ventures and CASSTAR, with Former Apple NPU Executives Betting on Edge General-Purpose Computing Platform | Unity Ventures

Secured nearly RMB 1 billion in funding across three rounds, all led by strategic corporate investors, within its first year.